



Fate Therapeutics, Inc.
Investor Relations Department
3535 General Atomics Ct.
Suite 200
San Diego, CA 92121
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: FATE

Last Trade:	4.14
Trade Time:	4:00 PM ET Dec 11, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	2.40 - 5.68
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 11, 2017

[Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage](#)

Dec 11, 2017

[Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500](#)

Dec 9, 2017

[Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8αβ+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy](#)

Dec 8, 2017

[Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer](#)

Dec 6, 2017

[Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 16, 2017

[Annual Report \(10-K\)](#)

Mar 22, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 14, 2017

[Quarterly Report \(10-Q\)](#)

May 15, 2017

[Quarterly Report \(10-Q\)](#)